| Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology JA Ajani, TA D'Amico, K Almhanna, DJ Bentrem, J Chao, P Das, ... Journal of the National Comprehensive Cancer Network 14 (10), 1286-1312, 2016 | 953 | 2016 |
| Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology JA Ajani, TA D’Amico, DJ Bentrem, J Chao, D Cooke, C Corvera, P Das, ... Journal of the National Comprehensive Cancer Network 20 (2), 167-192, 2022 | 905 | 2022 |
| Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology JA Ajani, TA D’Amico, DJ Bentrem, J Chao, C Corvera, P Das, ... Journal of the National Comprehensive Cancer Network 17 (7), 855-883, 2019 | 857 | 2019 |
| Gastric cancer, version 2.2013 JA Ajani, DJ Bentrem, S Besh, TA D’Amico, P Das, C Denlinger, MG Fakih, ... Journal of the national comprehensive cancer network 11 (5), 531-546, 2013 | 650 | 2013 |
| Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma MA Shah, RK Ramanathan, DH Ilson, A Levnor, D D'Adamo, E O'Reilly, ... Journal of Clinical Oncology 24 (33), 5201-5206, 2006 | 580 | 2006 |
| Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face F Fata, E O'Reilly, D Ilson, D Pfister, D Leffel, DP Kelsen, GK Schwartz, ... Cancer 86 (10), 2034-2037, 1999 | 536 | 1999 |
| Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma K Kawakami, J Brabender, RV Lord, S Groshen, BD Greenwald, ... Journal of the National Cancer Institute 92 (22), 1805-1811, 2000 | 466 | 2000 |
| Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial K Shitara, T Doi, M Dvorkin, W Mansoor, HT Arkenau, A Prokharau, ... The Lancet Oncology 19 (11), 1437-1448, 2018 | 453 | 2018 |
| Whole Body 18FDG-PET and the Response of Esophageal Cancer to Induction Therapy: Results of a Prospective Trial RJ Downey, T Akhurst, D Ilson, R Ginsberg, MS Bains, M Gonen, H Koong, ... Journal of clinical oncology 21 (3), 428-432, 2003 | 419 | 2003 |
| Esophageal and esophagogastric junction cancers, version 1.2015 JA Ajani, TA D’Amico, K Almhanna, DJ Bentrem, S Besh, J Chao, P Das, ... Journal of the National Comprehensive Cancer Network 13 (2), 194-227, 2015 | 382 | 2015 |
| Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus JA Ajani, DH Ilson, K Daugherty, R Pazdur, PM Lynch, DP Kelsen JNCI: Journal of the National Cancer Institute 86 (14), 1086-1091, 1994 | 371 | 1994 |
| Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer DH Ilson, L Saltz, P Enzinger, Y Huang, A Kornblith, M Gollub, E O'Reilly, ... Journal of Clinical Oncology 17 (10), 3270-3275, 1999 | 345 | 1999 |
| Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised … DVT Catenacci, NC Tebbutt, I Davidenko, AM Murad, SE Al-Batran, ... The lancet oncology 18 (11), 1467-1482, 2017 | 339 | 2017 |
| Genetic predictors of response to systemic therapy in esophagogastric cancer YY Janjigian, F Sanchez-Vega, P Jonsson, WK Chatila, JF Hechtman, ... Cancer discovery 8 (1), 49-58, 2018 | 335 | 2018 |
| Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer A Grann, BD Minsky, AM Cohen, L Saltz, JG Guillem, PB Paty, DP Kelsen, ... Diseases of the colon & rectum 40 (5), 515-522, 1997 | 324 | 1997 |
| First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial YY Janjigian, SB Maron, WK Chatila, B Millang, SS Chavan, C Alterman, ... The Lancet Oncology 21 (6), 821-831, 2020 | 312 | 2020 |
| Zolbetuximab plus mFOLFOX6 in patients with CLDN18. 2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction … K Shitara, F Lordick, YJ Bang, P Enzinger, D Ilson, MA Shah, ... The Lancet 401 (10389), 1655-1668, 2023 | 285 | 2023 |
| Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. DH Ilson, J Ajani, K Bhalla, A Forastiere, Y Huang, P Patel, L Martin, ... Journal of clinical oncology 16 (5), 1826-1834, 1998 | 281 | 1998 |
| Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma GK Schwartz, D Ilson, L Saltz, E O’Reilly, W Tong, P Maslak, J Werner, ... Journal of Clinical Oncology 19 (7), 1985-1992, 2001 | 278 | 2001 |
| Esophageal and esophagogastric junction cancers JA Ajani, JS Barthel, DJ Bentrem, TA D'Amico, P Das, CS Denlinger, ... Journal of the National Comprehensive Cancer Network 9 (8), 830-887, 2011 | 277 | 2011 |
